50-32-224. Specific dangerous drugs included in Schedule II. Schedule II consists of the drugs and other substances, by whatever official, common, usual, chemical, or brand name designated, listed in this section.
(1) Substances, vegetable origin or chemical synthesis. Unless specifically excepted or listed in another schedule, any of the following substances, whether produced directly or indirectly by extraction from substances of vegetable origin, independently by means of chemical synthesis, or by a combination of extraction and chemical synthesis, are included in this category:
(a) opium and opiate and any salt, compound, derivative, or preparation of opium or opiate, excluding apomorphine, thebaine-derived butorphanol, dextrorphan, nalbuphine, nalmefene, naloxone, naltrexone, and naloxegol and their respective salts, but including the following:
(i) raw opium;
(ii) opium extracts;
(iii) opium fluid;
(iv) powdered opium;
(v) granulated opium;
(vi) tincture of opium;
(vii) codeine;
(viii) dihydroetorphine;
(ix) ethylmorphine;
(x) etorphine hydrochloride;
(xi) hydrocodone;
(xii) hydromorphone;
(xiii) metopon;
(xiv) morphine;
(xv) oripavine;
(xvi) oxycodone;
(xvii) oxymorphone; and
(xviii) thebaine;
(b) any salt, compound, derivative, or preparation of them that is chemically equivalent or identical with any of the substances referred to in subsection (1)(a), except that these substances do not include the isoquinoline alkaloids of opium;
(c) opium poppy and poppy straw;
(d) coca leaves and any salt, compound, derivative, or preparation of coca leaves, including cocaine and ecgonine and their salts, isomers, derivatives, and salts of isomers, and derivatives, and any salt, compound, derivative, or preparation of them that is chemically equivalent or identical with any of these substances, except that these substances do not include decocainized coca leaves or extraction of coca leaves, which extractions do not contain cocaine or ecgonine; and
(e) concentrate of poppy straw, the crude extract of poppy straw in either liquid, solid, or powder form that contains the phenanthrene alkaloids of the opium poppy.
(2) Opiates. Unless specifically excepted or listed in another schedule, any of the following are opiates, including isomers, esters, ethers, salts, and salts of isomers, esters, and ethers whenever the existence of those isomers, esters, ethers, and salts is possible within the specific chemical designation, dextrorphan and levopropoxyphene excepted:
(a) alfentanil;
(b) alphaprodine;
(c) anileridine;
(d) bezitramide;
(e) bulk dextropropoxyphene (nondosage forms);
(f) carfentanil;
(g) dihydrocodeine;
(h) diphenoxylate;
(i) fentanyl;
(j) isomethadone;
(k) levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol, levomethadyl acetate, and LAAM;
(l) levomethorphan;
(m) levorphanol;
(n) metazocine;
(o) methadone;
(p) methadone-intermediate, 4-cyano-2-dimethylamino-4, 4-diphenyl butane;
(q) moramide-intermediate, 2-methyl-3-morpholino-1, 1-diphenylpropane-carboxylic acid;
(r) pethidine, also known as meperidine;
(s) pethidine-intermediate-A, 4-cyano-1-methyl-4-phenylpiperidine;
(t) pethidine-intermediate-B, ethyl-4-phenylpiperidine-4-carboxylate;
(u) pethidine-intermediate-C, 1-methyl-4-phenylpiperidine-4-carboxylic acid;
(v) phenazocine;
(w) piminodine;
(x) racemethorphan;
(y) racemorphan;
(z) remifentanil;
(aa) sufentanil;
(bb) tapentadol; and
(cc) thiafentanil.
(3) Stimulants. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is a stimulant having a stimulant effect on the central nervous system:
(a) amphetamine, its salts, optical isomers, and salts of its optical isomers;
(b) phenmetrazine and its salts;
(c) lisdexamfetamine, its salts, isomers, and salts of its isomers;
(d) methamphetamine, its salts, isomers, and salts of its isomers; and
(e) methylphenidate.
(4) Depressants. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is a depressant having a depressant effect on the central nervous system, including salts, isomers, and salts of isomers whenever the existence of those salts, isomers, and salts of isomers is possible within the specific chemical designation:
(a) amobarbital;
(b) glutethimide;
(c) pentobarbital;
(d) phencyclidine; and
(e) secobarbital.
(5) Hallucinogenic substances include the following:
(a) dronabinol in oral solution in a drug product approved for marketing by the United States food and drug administration;
(b) nabilone, also known as (levo-dextro)-trans-3-(1, 1-dimethylheptyl)-6,6-alpha,7,8,10,10-alpha-hexahydro-1-hydroxy-6,6-dimethyl-9H-dibenzo[b, d] pyran-9-one.
(6) Immediate precursors. Unless specifically excepted or listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances is an immediate precursor:
(a) 4-Anilino-N-phenethyl-4-piperidine (ANPP);
(b) phenylacetone, an immediate precursor to amphetamine and methamphetamine, also known as phenyl-2-propanone, P2P, benzyl methyl ketone, and methyl benzyl ketone; and
(c) 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile (PCC), immediate precursors to phencyclidine (PCP).
History: En. Sec. 7, Ch. 412, L. 1973; R.C.M. 1947, 54-307; amd. Sec. 2, Ch. 141, L. 1983; amd. Sec. 2, Ch. 36, L. 1991; amd. Sec. 3, Ch. 113, L. 1997; amd. Sec. 7, Ch. 135, L. 2013; amd. Sec. 2, Ch. 134, L. 2019.
Structure Montana Code Annotated
Chapter 32. Controlled Substances
Part 2. Scheduling of Dangerous Drugs
50-32-201. General criteria to be considered
50-32-202. Designation of drug as dangerous drug
50-32-203. Effect of rescheduling under federal law
50-32-204. Immediate precursors
50-32-205. Nonprescription drugs not to be scheduled
50-32-206. Use of names of scheduled drugs
50-32-207. Order forms for drugs in Schedules I and II
50-32-208. Prescription and medical requirements for scheduled drugs -- penalty
50-32-209. Republication of schedules
50-32-210. through 50-32-220 reserved
50-32-221. Criteria for placement of drug in Schedule I
50-32-222. Specific dangerous drugs included in Schedule I
50-32-223. Criteria for placement of drug in Schedule II
50-32-224. Specific dangerous drugs included in Schedule II
50-32-225. Criteria for placement of drug in Schedule III
50-32-226. Specific dangerous drugs included in Schedule III
50-32-227. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule III
50-32-228. Criteria for placement of drug in Schedule IV
50-32-229. Specific dangerous drugs included in Schedule IV
50-32-230. Board authorized to exempt certain compounds, mixtures, or preparations from Schedule IV
50-32-231. Criteria for placement of drug in Schedule V